Phase 1 study of OXC-101 in Acute myeloid leukaemia
Latest Information Update: 31 May 2023
At a glance
- Drugs Karonudib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms MAATEO
- Sponsors Oxcia
Most Recent Events
- 31 May 2023 New trial record
- 03 Apr 2023 According to a Oxcia media release, the company collaborates closely with Karolinska Institute, Karolinska University Hospital and Orebro University Hospital to demonstrate efficacy as well as further proof of safety in monotherapy as well as in combination with chemotherapy in refractory/relapsed AML.